Western Regional Community Clinical Oncology Program
西部地区社区临床肿瘤学计划
基本信息
- 批准号:6786043
- 负责人:
- 金额:$ 56.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1983
- 资助国家:美国
- 起止时间:1983-09-01 至 2006-05-31
- 项目状态:已结题
- 来源:
- 关键词:antineoplastic antibioticsaspirinbone marrow transplantationbrain neoplasmsbreast neoplasmscancer information systemcancer preventioncancer registry /resourcecancer rehabilitation /carechemopreventionclinical researchclinical trialscolony stimulating factorcombination cancer therapycooperative studyfemale reproductive system neoplasmgastrointestinal neoplasmshealth disparityhormone therapyhuman subjecthuman therapy evaluationleukemialung neoplasmslymphomamedical rehabilitation related tagmedically underserved populationmultiple myelomaneoplasm /cancer chemotherapyneoplasm /cancer educationneoplasm /cancer immunotherapyneoplasm /cancer radiation therapyneoplasm /cancer surgeryoncology nursingprimary care physicianprostate neoplasmstumor necrosis factor alphaurinary tract neoplasms
项目摘要
DESCRIPTION (provided by applicant): The Greater Phoenix CCOP is a consortium of five hospitals with 40 investigators, led by principal investigator, David King, MD. Dr. King and many of the investigators have been associated with the CCOP since its inception in 1982. The continuing long-term goals and specific aims of the GPCCOP include: 1) To increase clinical research activities with new and established research bases; 2) To participate in chemoprevention studies supported through other NCI mechanisms, to enhance offerings to GPCCOP's population; 4) To maintain and enhance quality assurance and pharmacy tools to support GPCCOP accrual; 5) To provide for human subject protection and minimal research risk; and 6) To support the disease prevention objectives of "Healthy People 2010" - in particular, to eliminate health disparities among different segments of the population through outreach, affiliations, and recruitment strategies focusing on minorities, women, and the underserved. GPCCOP's organizational structure requires the involvement of the investigators, hospital administrators from each of the participating component organizations and the staff in planning and policy-making decisions. The research activities and resources are split evenly between the treatment segment and the chemoprevention segment of GPCCOP, with each segment achieving accrual and quality goals established by the National Cancer Institute. GPCCOP's outreach is focused on achieving goals of minority and underserved accrual through community affiliations, collaborations, and geographical diversity. By establishing community and tribal partnerships, GPCCOP facilitates an outreach territory encompassing more that 40,000 square miles and 4 counties. GPCCOP's dedication to participant accrual (205 treatment and more than 1000 chemoprevention participants in the past five years), quality assurance, human subject protection, and minority outreach, as well as the devotion of resources from its consortium hospitals, demonstrate its preparedness to continue its active participation in NCI's Community Clinical Oncology Program.
描述(由申请人提供):大凤凰CCOP是一个由五家医院组成的联盟,有40名调查员,由首席调查员大卫·金领导。自1982年CCOP成立以来,金博士和许多调查人员一直与其有联系。GPCCOP持续的长期目标和具体目标包括:1)通过新的和建立的研究基地增加临床研究活动;2)参与通过其他NCI机制支持的化学预防研究,以加强向GPCCOP人口提供的服务;4)保持和加强质量保证和药剂学工具,以支持GPCCOP的应计;5)提供人体受试者保护和将研究风险降至最低;以及6)支持“2010年健康人”的疾病预防目标--特别是通过以少数群体、妇女和未得到充分服务的人群为重点的外联、联系和招募战略,消除不同人口群体之间的健康差距。GPCCOP的组织结构要求调查人员、每个参与组织的医院管理人员和工作人员参与规划和决策。研究活动和资源平均分配到GPCCOP的治疗部分和化学预防部分,每个部分都实现了国家癌症研究所制定的应计和质量目标。GPCCOP的外展重点是通过社区联系、合作和地理多样性实现少数群体和服务不足的目标。通过建立社区和部落伙伴关系,GPCCOP促进了覆盖40,000多平方英里和4个县的外展领土。GPCCOP致力于参与者应计(在过去五年中有205项治疗和1000多名化学预防参与者)、质量保证、人类受试者保护和少数群体宣传,以及其联盟医院的资源投入,表明其准备继续积极参与NCI的社区临床肿瘤学计划。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID K KING其他文献
DAVID K KING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID K KING', 18)}}的其他基金
GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM
大菲尼克斯社区临床肿瘤学计划
- 批准号:
2653984 - 财政年份:1983
- 资助金额:
$ 56.26万 - 项目类别:
GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM
大菲尼克斯社区临床肿瘤学计划
- 批准号:
3557649 - 财政年份:1983
- 资助金额:
$ 56.26万 - 项目类别:
GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM
大菲尼克斯社区临床肿瘤学计划
- 批准号:
2088898 - 财政年份:1983
- 资助金额:
$ 56.26万 - 项目类别:
GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM
大菲尼克斯社区临床肿瘤学计划
- 批准号:
3557650 - 财政年份:1983
- 资助金额:
$ 56.26万 - 项目类别:
GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM
大菲尼克斯社区临床肿瘤学计划
- 批准号:
2088900 - 财政年份:1983
- 资助金额:
$ 56.26万 - 项目类别:
GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM
大菲尼克斯社区临床肿瘤学计划
- 批准号:
3557655 - 财政年份:1983
- 资助金额:
$ 56.26万 - 项目类别:
GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM
大菲尼克斯社区临床肿瘤学计划
- 批准号:
6171984 - 财政年份:1983
- 资助金额:
$ 56.26万 - 项目类别:
相似国自然基金
Aspirin调控AKT/Foxo3a/BIM通路延缓吡咯替尼耐药作用机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:0.0 万元
- 项目类别:省市级项目
Aspirin与自噬通路及核转录因子FoxG1在听觉系统退行性变中的协同调控机制研究
- 批准号:81800915
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
Aspirin联合牙周膜干细胞再生全脱位牙牙周组织机制研究
- 批准号:81760190
- 批准年份:2017
- 资助金额:32.0 万元
- 项目类别:地区科学基金项目
可注射温敏型水凝胶缓释Aspirin碳点和EPO促牙周组织再生的研究
- 批准号:81600879
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
Aspirin协同IFN-α抑制肝癌转移复发的作用及机制研究
- 批准号:30972889
- 批准年份:2009
- 资助金额:31.0 万元
- 项目类别:面上项目
胃癌microRNA特异表达与靶基因调控及Aspirin的作用
- 批准号:30873099
- 批准年份:2008
- 资助金额:35.0 万元
- 项目类别:面上项目
相似海外基金
Impacts of Acute Ambient Air Pollution Exposure on Women's Reproductive Health: Identifying Mechanisms and Susceptible Reproductive Processes Across the Menstrual Cycle and Early Pregnancy
急性环境空气污染暴露对女性生殖健康的影响:确定月经周期和怀孕早期的机制和易受影响的生殖过程
- 批准号:
10645818 - 财政年份:2023
- 资助金额:
$ 56.26万 - 项目类别:
Novel Mechanisms Underlying the Development of Atherosclerosis
动脉粥样硬化发展的新机制
- 批准号:
10589484 - 财政年份:2023
- 资助金额:
$ 56.26万 - 项目类别:
Improved optimization of covalent ligands using a novel implementation of quantum mechanics suitable for large ligand/protein systems.
使用适用于大型配体/蛋白质系统的量子力学的新颖实现改进了共价配体的优化。
- 批准号:
10601968 - 财政年份:2023
- 资助金额:
$ 56.26万 - 项目类别:
NETs as therapeutic targets in obstetric APS
NETs 作为产科 APS 的治疗靶点
- 批准号:
10786977 - 财政年份:2023
- 资助金额:
$ 56.26万 - 项目类别:
Aspirin, Lp(a) and Primary Prevention of Cardiovascular Events
阿司匹林、Lp(a) 和心血管事件的一级预防
- 批准号:
10720757 - 财政年份:2023
- 资助金额:
$ 56.26万 - 项目类别:
Postpartum low-dose aspirin to augment vascular recovery following a hypertensive disorder of pregnancy
产后小剂量阿司匹林可促进妊娠高血压疾病后的血管恢复
- 批准号:
10644089 - 财政年份:2023
- 资助金额:
$ 56.26万 - 项目类别:
Precision Pharmacogenomic Perioperative Prediction
精准药物基因组围手术期预测
- 批准号:
10643419 - 财政年份:2023
- 资助金额:
$ 56.26万 - 项目类别:
Early Double Low-Dose Aspirin to Reduce Preeclampsia and Miscarriage: a Global Approach RCT
早期双倍低剂量阿司匹林减少先兆子痫和流产:全球方法随机对照试验
- 批准号:
10711793 - 财政年份:2023
- 资助金额:
$ 56.26万 - 项目类别:
Coronary artery calcium synthetic cohort and lifetime percentile project (CACSC-LPP)
冠状动脉钙合成队列和终生百分位项目 (CACSC-LPP)
- 批准号:
10731429 - 财政年份:2023
- 资助金额:
$ 56.26万 - 项目类别: